Tag: program

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.¹ The results showed that TALVEY^® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).¹ Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.¹  

MIAMI, FL, June 13, 2026 (GLOBE NEWSWIRE) -- Dengan SpaceX (NASDAQ: SPCX) dijangka mula didagangkan di Nasdaq hari ini, Defiance ETFs mengesahkan bahawa Defiance Daily 2X Space ETF (Cboe: SPCL) akan menyasarkan pendedahan berleveraj harian 2X kepada saham biasa Kelas A SpaceX dalam portfolionya. Langkah ini menjadikan SPCL sebagai dana dagangan bursa (ETF) pertama dan satu-satunya di Amerika Syarikat yang mempunyai pendedahan 2X kepada SpaceX pada hari IPO. Pendedahan SpaceX dalam dana tersebut ditetapkan pada harga IPO sebanyak USD135 sesaham.